FBXO47 Inhibitors

Skp1 Inhibitor impedes the assembly of the SCF complex, which is critical for FBXO47's role in protein ubiquitination. Similarly, the Nedd8-Activating Enzyme Inhibitor known as MLN4924 obstructs the neddylation of cullin proteins, a post-translational modification necessary for the activation of cullin-RING ligases, consequently affecting the ubiquitination activity associated with FBXO47. On the other hand, the Proteasome Inhibitor MG132 brings about a blockade in the degradation pathway of ubiquitinated proteins, creating a backlog of substrates that would typically be targeted by FBXO47 for degradation. This accumulation provides indirect evidence of the substrates and the ubiquitination activity of FBXO47. The Ubiquitin-Activating Enzyme E1 Inhibitor disrupts the activation of ubiquitin itself, an initial and crucial step in the ubiquitination cascade, thereby diminishing the ubiquitination that FBXO47 mediates. Curcumin, a Cullin-RING Ligase Inhibitor, hampers the ubiquitination process by affecting the cullin-RING ligases' (CRLs) activity, which are the ubiquitin ligases where FBXO47 is a component. The inhibition of the JNK pathway through SP600125 and GSK3β with lithium chloride (LiCl) influences the regulation of protein degradation, which could lead to altered stability of FBXO47 substrates. Similarly, the CK1 Inhibitor D4476 affects the regulation of the SCF complex, which could lead to changes in FBXO47 activity. Furthermore, compounds like Nutlin-3 stabilize p53, a potential substrate of FBXO47, thereby possibly influencing its degradation by FBXO47. Brusatol, which disrupts the Keap1-Nrf2 interaction, might affect the ability of FBXO47 to ubiquitinate Nrf2 if it were a substrate. The Autophagy Inhibitor Chloroquine results in the accumulation of ubiquitinated proteins by inhibiting autophagy, providing insight into the effects of ubiquitin-mediated turnover modulated by FBXO47.